Targeted Oncology20m
FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...
Targeted Oncology1h
Survival Gains and Challenges: The CROSS Trial in GEJ Cancer
Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction ...
Targeted Oncology3h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Targeted Oncology6h
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Targeted Oncology6h
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...
Targeted Oncology8h
Adverse Event Management: Amivantamab
Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...
Targeted Oncology21h
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease
In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their ...